In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daniel Chancellor

VP Thought Leadership for Norstella

London, UK

Daniel has more than 15 years of experience in the biopharma industry, spanning roles in drug discovery, market analysis, competitive intelligence, and strategic consulting. Beginning his advisory career at Citeline, Daniel now oversees the thought leadership program for Norstella and its constituent companies, producing materials that support clients across a range of hot topics in the biopharma industry. As part of this, Daniel regularly participates in webinars, conferences, and other speaking arrangements, and he has provided expert insights across a wide range of leading industry and business publications. Prior to joining Citeline, Daniel worked as a medicinal chemist at the UK biotech company Summit Therapeutics and graduated with First Class Honors in Natural Sciences from the University of Bath.

Latest From Daniel Chancellor

Why Are Clinical Development Success Rates Falling?

A recent analysis from Biomedtracker of clinical trial phase transitions between 2014 and 2023 suggests biopharma development success rates are falling. This poses several questions: what are the underlying reasons dragging success rates down and what does this mean for R&D productivity and the return on investment on pipeline spend?

Clinical Trials Market Intelligence

France: A European Leader In Rare Diseases

France has long been a European leader in rare diseases, from its scientific research and academic hospitals, through to patient advocacy and regulatory reforms that have encouraged R&D. Its biotech and pharmaceutical industries are now leading the way, discovering the next generation of therapies for patients that are often overlooked.

Rare Diseases France

The Next Mega-Blockbusters Are Already Approved

The success of a drug depends on investment and lifecycle management. Keytruda is the most valuable drug in the industry, while trendy GLP-1 agonists are a prominent drug class. 

Commercial Sales & Earnings

The Growing Pains Of Chinese Biotech

The emergence of China from API manufacturer to an innovation leader, fuelled by domestic investments and home-grown talent, has been one of the most remarkable trends of the last decade.

Asia Pacific China

The State Of TechBio Going Into 2024

The long-term success of TechBio is dependent upon the flow of investment and alliances with mature life sciences companies. This collaborative model has proven many times over to be an ideal framework to develop new treatments for patients.

Artificial Intelligence Business Strategies

The Misalignment Of Pharma Pipelines

Portfolio decisions for pharma pipelines are multifactorial, although patient need perhaps does not get the attention it merits. Rather, the gravitational pull around risk, investment return, and regulatory incentive tilts the pharma pipeline toward overconcentration in hot therapy areas.

Research & Development Strategy
See All